These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 30977836)

  • 1. Response to a letter to the editor, "Studying the incidence of thyroid cancer in Ecuador: 2016-2021".
    Paz-Cruz E; Cadena-Ullauri S; Guevara-Ramírez P; Ruiz-Pozo VA; Tamayo-Trujillo R; Simancas-Racines D; Zambrano AK
    Heliyon; 2024 May; 10(10):e30963. PubMed ID: 38803986
    [No Abstract]   [Full Text] [Related]  

  • 2. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.
    Kazakou P; Tzanetakos D; Vakrakou AG; Tzartos JS; Evangelopoulos ΜE; Anagnostouli M; Stathopoulos P; Kassi GN; Stefanis L; Kilidireas C; Zapanti E
    Clin Exp Med; 2023 Oct; 23(6):2885-2894. PubMed ID: 36641771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter to the Editor: "Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features".
    Garrahy A; Murphy NP; Byrne MM
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3624-3625. PubMed ID: 30977837
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
    Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
    Trinh T; Haridas AS; Sullivan TJ
    Ophthalmic Plast Reconstr Surg; 2016; 32(6):e128-e129. PubMed ID: 25794019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Letter to the Editor: "Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features".
    Thakar R; Gajewska-Knapik K; Ogilvy-Stuart AL; Chatterjee K; Moran C
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3626-3627. PubMed ID: 30977836
    [No Abstract]   [Full Text] [Related]  

  • 8. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management.
    Mahzari M; Arnaout A; Freedman MS
    Can J Neurol Sci; 2015 Sep; 42(5):284-91. PubMed ID: 25990097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
    Ruck T; Bittner S; Wiendl H; Meuth SG
    Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.
    Kennedy B; Hillmen P
    Med Oncol; 2002; 19 Suppl():S49-55. PubMed ID: 12180492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.
    Zinzani PL; Corradini P; Gallamini A; Grossi A; Lazzarino M; Marchetti M; Martelli M; Rossi G; Vitolo U
    Leuk Lymphoma; 2012 May; 53(5):789-95. PubMed ID: 21980956
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.